BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26886301)

  • 1. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
    Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
    J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
    Kumalo HM; Bhakat S; Soliman ME
    Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-targeting of mTOR and HSP90 for cancer therapy: facing oncogenic feed-back-loops and acquired mTOR resistance.
    Stoeltzing O
    Cell Cycle; 2010 Jun; 9(11):2051-2. PubMed ID: 20505332
    [No Abstract]   [Full Text] [Related]  

  • 4. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
    Jhaveri K; Modi S
    Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
    Siegelin MD
    Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
    Solárová Z; Mojžiš J; Solár P
    Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock proteins and cancer: How can nanomedicine be harnessed?
    Sauvage F; Messaoudi S; Fattal E; Barratt G; Vergnaud-Gauduchon J
    J Control Release; 2017 Feb; 248():133-143. PubMed ID: 28088573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
    Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
    Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer Therapy.
    Proia DA; Kaufmann GF
    Cancer Immunol Res; 2015 Jun; 3(6):583-9. PubMed ID: 25948551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging Roles of Extracellular Hsp90 in Cancer.
    Wong DS; Jay DG
    Adv Cancer Res; 2016; 129():141-63. PubMed ID: 26916004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
    Proia DA; Bates RC
    Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
    Xiao Y; Liu Y
    Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HSP90 as a platform for the assembly of more effective cancer chemotherapy.
    Whitesell L; Lin NU
    Biochim Biophys Acta; 2012 Mar; 1823(3):756-66. PubMed ID: 22222203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Evaluation and Biomarker Profiling of Hsp90 Inhibitors.
    Yuno A; Lee MJ; Lee S; Tomita Y; Rekhtman D; Moore B; Trepel JB
    Methods Mol Biol; 2018; 1709():423-441. PubMed ID: 29177675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.